Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma

NCT00680225 Phase 3 COMPLETED Results posted

To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

Details

Lead sponsor	New England Retina Associates
Phase	Phase 3
Status	COMPLETED
Enrolment	10
Start date	2007-09
Completion	2012-07

Conditions

• Choroidal Melanoma

Interventions

• Ranibizumab injection and TTT - ICG based

Primary outcomes

• Mean Tumor Thickness — 12 mo

Countries

United States